What type of study is this?

November 30, 2025Open Access

Clinical outcomes after switching from omalizumab to anti-IL-5/IL-5R biologics in severe asthma: a retrospective cohort study

Key Points

Switching from omalizumab to IL-5 biologics improves clinical outcomes in severe asthma patients.
Key predictors for treatment change were identified based on baseline clinical parameters.
Retrospective cohort analysis evaluated the effectiveness of changing biological therapies.
Findings suggest potential benefits of tailored biologic treatment strategies in severe asthma cases.

Abstract

In severe asthma patients who do not achieve adequate control with omalizumab, switching to interleukin-5 (IL-5) targeted biological therapies may provide clinically significant improvements. Baseline clinical parameters can serve as useful predictors for the need to change biological treatment.

Clinical outcomes after switching from omalizumab to anti-IL-5/IL-5R biologics in severe asthma: a retrospective cohort study

Key Points

Abstract

Cite This Study